AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Molecular Targeting Technologies, Inc. has received a $3.17M grant from the National Cancer Institute to support the development of ¹⁷⁷Lu-EBRGD for non-small cell lung cancer.
Amount Raised
$3.17 Million
Round Type
Seed
West ChesterBiotechnologyHealth CareDescription
Molecular Targeting Technologies, based in West Chester, PA, has been awarded a $3.17M five-year grant from the National Cancer Institute. The funding will advance the development of an investigational radiopharmaceutical targeting integrin αvβ3 for non-small cell lung cancer. This award will support various activities, including preclinical research and planned clinical studies. The aim is to establish a robust foundation for evaluating ¹⁷⁷Lu-EBRGD in patients.
Fundz sees it the moment Molecular Targeting Technologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Molecular Targeting Technologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.